跳至主要内容
临床试验/DRKS00025993
DRKS00025993尚未招募不适用

Observational study to evaluate acceptability and bleeding profile with Drospirenone 4 mg, in a regimen of use 24/4 in contraception (Slinda®, Exeltis HealthCare) after six months of use. - EXELINDA

Exeltis Healthcare0 个研究点目标入组 300 人开始时间: 2021年8月6日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 50 Years(—)
性别
Female

入选标准

  • 1.Women over 18 years up to 50 years.
  • 2. They use Slinda ® for the approved indication (contraception) and have started treatment at least 6 months before the visit.
  • 3. They shall give informed consent in order to participate in the study.

排除标准

  • 未提供

研究者

发起方
Exeltis Healthcare

相似试验